Wenjing Ying1, Danru Liu1, Xiaolong Dong1, Wenjie Wang1, Xiaoying Hui1, Jia Hou1, Haili Yao1, Qinhua Zhou1, Bijun Sun1, Jinqiao Sun2, Xiaochuan Wang3. 1. Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. 2. Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. jinqiaosun@fudan.edu.cn. 3. Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai, 201102, China. xchwang@shmu.edu.cn.
Abstract
PURPOSE: Although many studies have investigated Mendelian susceptibility to mycobacterial disease (MSMD) worldwide, there is no report of the long-term clinical management and prognosis for MSMD in China. METHODS: This is a cohort study from January 2000 to June 2018. Three hundred and twenty-four patients with bacillus Calmette-Guérin (BCG) infection were diagnosed during this period, and those with MSMD diagnosed by genetic and functional experiments were enrolled in the study. The clinical and genetic characteristics and management of these MSMD patients were summarized. RESULTS: Thirty patients diagnosed with MSMD were followed up. The age at the follow-up end point ranged from 5 to 173 months. Among the patients, IL12RB1 mutations were identified in 22, IFNGR1 mutations in 5, STAT1 mutations in 2, and IFNGR2 mutation in 1. The medium age at onset was 3 months. BCG infection involved multiple organs, including regional infection (8/30; 26.7%) or distant or disseminated infection (22/30; 73.3%). Ten percent (30/324) of patients with BCG infection had a confirmed MSMD diagnosis. Protein expression of IL12RB1 or IFNGR1 was decreased in all patients with IL12RB1 or IFNGR1 mutation, respectively, as indicated by flow cytometry. In addition, 77.8% of patients received rhIFN-γ treatment, which can improve the prognosis of patients with IL12RB1 deficiency. Two patients received stem cell transplantation. Twenty-five patients remained alive at the time of publication. CONCLUSION: MSMD is an important cause of BCG infection. Flow cytometric detection of IL12RB1 and IFNGR1 expression is very useful for rapid MSMD diagnosis. rhIFN-γ therapy is effective in patients with MSMD, particularly improving prognosis in those with IL12RB1 deficiency.
PURPOSE: Although many studies have investigated Mendelian susceptibility to mycobacterial disease (MSMD) worldwide, there is no report of the long-term clinical management and prognosis for MSMD in China. METHODS: This is a cohort study from January 2000 to June 2018. Three hundred and twenty-four patients with bacillus Calmette-Guérin (BCG) infection were diagnosed during this period, and those with MSMD diagnosed by genetic and functional experiments were enrolled in the study. The clinical and genetic characteristics and management of these MSMD patients were summarized. RESULTS: Thirty patients diagnosed with MSMD were followed up. The age at the follow-up end point ranged from 5 to 173 months. Among the patients, IL12RB1 mutations were identified in 22, IFNGR1 mutations in 5, STAT1 mutations in 2, and IFNGR2 mutation in 1. The medium age at onset was 3 months. BCG infection involved multiple organs, including regional infection (8/30; 26.7%) or distant or disseminated infection (22/30; 73.3%). Ten percent (30/324) of patients with BCG infection had a confirmed MSMD diagnosis. Protein expression of IL12RB1 or IFNGR1 was decreased in all patients with IL12RB1 or IFNGR1 mutation, respectively, as indicated by flow cytometry. In addition, 77.8% of patients received rhIFN-γ treatment, which can improve the prognosis of patients with IL12RB1 deficiency. Two patients received stem cell transplantation. Twenty-five patients remained alive at the time of publication. CONCLUSION: MSMD is an important cause of BCG infection. Flow cytometric detection of IL12RB1 and IFNGR1 expression is very useful for rapid MSMD diagnosis. rhIFN-γ therapy is effective in patients with MSMD, particularly improving prognosis in those with IL12RB1 deficiency.
Authors: A C Hesseling; H Rabie; B J Marais; M Manders; M Lips; H S Schaaf; R P Gie; M F Cotton; P D van Helden; R M Warren; N Beyers Journal: Clin Infect Dis Date: 2006-01-11 Impact factor: 9.079
Authors: Calman MacLennan; Claire Fieschi; David A Lammas; Capucine Picard; Susan E Dorman; Ozden Sanal; Jenny M MacLennan; Steven M Holland; Tom H M Ottenhoff; Jean-Laurent Casanova; Dinakantha S Kumararatne Journal: J Infect Dis Date: 2004-10-07 Impact factor: 5.226
Authors: Elgin G R Lichtenauer-Kaligis; Tjitske de Boer; Frank A W Verreck; Sjaak van Voorden; Marieke A Hoeve; Esther van de Vosse; Fugen Ersoy; Ilhan Tezcan; Jaap T van Dissel; Ozden Sanal; Tom H M Ottenhoff Journal: Eur J Immunol Date: 2003-01 Impact factor: 5.532
Authors: Aileen M Cleary; Wenwei Tu; Andrea Enright; Thierry Giffon; Rene Dewaal-Malefyt; Kathleen Gutierrez; David B Lewis Journal: J Immunol Date: 2003-01-01 Impact factor: 5.422
Authors: Claire Fieschi; Stéphanie Dupuis; Emilie Catherinot; Jacqueline Feinberg; Jacinta Bustamante; Adrien Breiman; Frédéric Altare; Richard Baretto; Françoise Le Deist; Samer Kayal; Hartmut Koch; Darko Richter; Martin Brezina; Guzide Aksu; Phil Wood; Suliman Al-Jumaah; Miquel Raspall; Alberto José Da Silva Duarte; David Tuerlinckx; Jean-Louis Virelizier; Alain Fischer; Andrea Enright; Jutta Bernhöft; Aileen M Cleary; Christiane Vermylen; Carlos Rodriguez-Gallego; Graham Davies; Renate Blütters-Sawatzki; Claire-Anne Siegrist; Mohammad S Ehlayel; Vas Novelli; Walther H Haas; Jacob Levy; Joachim Freihorst; Sami Al-Hajjar; David Nadal; Dewton De Moraes Vasconcelos; Olle Jeppsson; Necil Kutukculer; Klara Frecerova; Isabel Caragol; David Lammas; Dinakantha S Kumararatne; Laurent Abel; Jean-Laurent Casanova Journal: J Exp Med Date: 2003-02-17 Impact factor: 14.307
Authors: Guang Xue He; Yan Lin Zhao; Guang Lu Jiang; Yu Hong Liu; Hui Xia; Sheng Fen Wang; Li Xia Wang; Martien W Borgdorff; Marieke J van der Werf; Susan van den Hof Journal: BMC Infect Dis Date: 2008-12-11 Impact factor: 3.090